Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study

摘要: Few studies have examined chemotherapy-induced peripheral neuropathy (CIPN) following the administration of eribulin as first- or second-line therapy in patients with breast cancer. We therefore assessed CIPN incidence by severity and risk factors for treated HER2-negative inoperable recurrent cancer, regardless line status. This multicenter, prospective, post-marketing observational study enrolled from September 2014 Japan followed them 2 years. For this interim analysis, data cut-off point was November 2017. based on Japanese version Common Terminology Criteria Adverse Events, 4.0. Among 634 included safety 374 did not existing at baseline. observed 105 (28.1%), including 67 (17.9%), 34 (9.1%), 4 (1.1%) grade 1, 2, 3 severity, respectively. Of patients, 85.7% continued, 7.6% reduced, interrupted postponed, 6.7% discontinued eribulin. The median time (min‒max) baseline to onset 60 (3‒337) days. Multivariate logistic regression identified a significant association between hemoglobin level baseline, starting dose eribulin, history radiotherapy. Our findings indicate that, respect CIPN, is well-tolerated, approximately one-quarter developed most cases were 1 majority continued after onset.